The massive dilution (~43% increase in shares outstanding from the offering alone, plus potential for up to 49.3M additional shares from warrants) will pressure the stock near-term. The common warrants' exercisability depends on a shareholder vote to increase authorized shares — if denied, the warrants are worthless, removing a future overhang but also signaling lack of support. Watch for the shareholder meeting within 60 days post-closing and any OS data release from the MICVO Phase 1 study, which could trigger early warrant expiration.
Price Chart
Executive Summary
Pyxis Oncology priced a $110.0 million underwritten public offering of 36,047,919 shares of common stock (and pre-funded warrants for 1,883,121 shares) with accompanying common warrants to purchase up to 49,310,352 shares at $3.50 per share. Net proceeds are ~$102.8 million to fund the lead ADC program MICVO through a planned Phase 3 trial in 2L+ R/M HNSCC and for working capital. The common warrants are contingent on stockholder approval to increase authorized shares and are exercisable only after a charter amendment becomes effective, creating significant uncertainty around their value.
Key Facts
- Offering of 36,047,919 common shares and pre-funded warrants for 1,883,121 shares, each with a common warrant to purchase 1.3 shares at $3.50.
- Total gross proceeds of $109,998,133; net proceeds of ~$102.8 million after underwriting discounts and estimated expenses.
- Common warrants exercisable only after stockholder approval to increase authorized shares (Charter Amendment); if not obtained, warrants may have zero value.
- Pro forma as-adjusted net tangible book value per share post-offering is $1.34, representing immediate dilution of $1.56 per share for new investors.
- Proceeds intended to fund MICVO (micvotabart pelidotin) through key milestones including planned Phase 3 Headliner trial in 2L+ R/M HNSCC.
- Existing cash plus net proceeds expected to fund operations into first half of 2028; if warrants not exercised, funds insufficient for full Phase 3 trial.
- Last reported stock price on September 29, 2026 was $2.90 per share.
- Underwriters include Leerink Partners, Guggenheim Securities, and Wells Fargo Securities.
Financial Impact
~$102.8 million net proceeds raised; immediate dilution of $1.56 per share for new investors (54% dilution from offering price of $2.90 to pro forma book value of $1.34).
Risk Factors
- Immediate and substantial dilution of ~54% from offering price to pro forma book value.
- Common warrants may never become exercisable if stockholder approval for charter amendment is not obtained, rendering them worthless.
- Net proceeds may be insufficient to fully fund the planned Phase 3 trial if warrants are not exercised.
- No public trading market for the warrants; limited liquidity.
- Pre-clinical stage company with no approved products or revenue; high cash burn rate.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-031667 |
| Document: 0001437749-26-031667-index-headers.html | 0001437749-26-031667 |
| Document: 0001437749-26-031667-index.html | 0001437749-26-031667 |
| Document: 0001437749-26-031667.txt | 0001437749-26-031667 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $1.66 | awaiting T+5 | — | $1.84 (+10.84%) |
Oct 21, 2026 6d ago | DEF 14A | $1.71 | awaiting T+5 | — | $1.84 (−7.60%) |
Oct 9, 2026 18d ago | SC 13G/A | $2.03 $1.68 | ▼ −17.24% | ▼ −15.27% | $1.84 (−9.36%) |
Oct 2, 2026 25d ago | SC 13G/A | $2.14 $2.03 | ▼ −5.14% | ▼ −6.30% | $1.84 (−14.02%) |
Oct 2, 2026 25d ago | Press Release | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 8-K | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 424B5 | $2.19 $1.99 | ▲ +9.13% | ▲ +10.43% | $1.84 (+15.98%) |
Sep 30, 2026 27d ago | Press Release | $2.33 $2.01 | ▲ +13.73% | ▲ +15.65% | $1.84 (+21.03%) |
Sep 9, 2026 6w ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $1.84 (−45.56%) |
Sep 8, 2026 7w ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $1.84 (−52.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers